Sage Therapeutics scraps Parkinson's drug development after treatment fails mid-stage study [Reuters]
Sage Therapeutics, Inc. (SAGE)
Last sage therapeutics, inc. earnings: 2/27 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.sagerx.com/investor-relations
Company Research
Source: Reuters
, opens new tab said on Wednesday it will stop development of its experimental drug to treat Parkinson's disease after it failed a mid-stage study, sending the company's shares down 4% before the bell. Parkinson's disease, a progressive movement disorder of the nervous system, affects about 1 million people in the United States. Sage Therapeutics' drug, dalzanemdor, did not show statistically significant differences in patients with mild cognitive impairment due to Parkinson's compared to a placebo, the company said. Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here. Reporting by Mariam Sunny in Bengaluru; Editing by Shounak Dasgupta Our Standards: The Thomson Reuters Trust Principles. New Tab , opens new tab
Show less
Read more
Impact Snapshot
Event Time:
SAGE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SAGE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SAGE alerts
High impacting Sage Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SAGE
News
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sage Therapeutics, Inc. - SAGEPR Newswire
- Earnings Update: Sage Therapeutics, Inc. (NASDAQ:SAGE) Just Reported And Analysts Are Boosting Their Estimates [Yahoo! Finance]Yahoo! Finance
- Sage Therapeutics, Inc. (NASDAQ: SAGE) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at HC Wainwright from $28.00 to $25.00. They now have a "neutral" rating on the stock.MarketBeat
- Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $28.00 to $19.00. They now have a "neutral" rating on the stock.MarketBeat
SAGE
Earnings
- 4/25/24 - Miss
SAGE
Sec Filings
- 4/25/24 - Form 10-Q
- 4/25/24 - Form 8-K
- 4/24/24 - Form ARS
- SAGE's page on the SEC website